Growth could moderate when Alnylam’s Amvuttra receives FDA approval in late March, but I continue to see a strong growth path ahead for Attruby considering its strong clinical profile.

Alnylam Pharmaceuticals currently has Amvuttra, its drug targeting ATTR amyloidosis with cardiomyopathy, under FDA review. Amvuttra is seen as a competitor to Attruby since the drug works to silence ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Huntington’s disease is a brain disorder that can affect various functions, including the ability to swallow — particularly as the disease progresses. Huntington’s disease is a ...

While Huntington’s disease is progressive and worsens over time, understanding what is to come can help someone with this condition plan for the road ahead. Huntington’s disease is a ...

Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR ...

In amyloidosis, Alnylam and Pfizer are seeing strong uptake of their treatments Amvuttra and Vyndaqel. It is unclear whether Wainua will alter this dynamic. Some patients in Tegsedi and Waylivra ...

Alnylam has two drugs for ATTR polyneuropathy – Onpattro (patisiran), which is given by intravenous infusion every three weeks, and newer Amvuttra (vutrisiran), which requires a doctor ...

Rachel Elfman is an equity analyst for Morningstar Research Services, a wholly owned subsidiary of Morningstar, Inc. She covers contract research organizations and biotechnology stocks. Before ...

Days after approving the drug, the FDA also accepted Alnylam’s competing medicine Amvuttra for review in the same indication. The FDA will make a decision on the label expansion for Amvuttra by March ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Sebastien Coppe, CEO, One2Treat, talks challenges faced by startups in advancing clinical trial innovation. ACT: You were a ...